Coya Therapeutics (COYA) Non-Current Assets (2021 - 2026)
Coya Therapeutics (COYA) posted Non-Current Assets of $8420.0 for Q1 2026, down 25.0% sequentially from $11227.0 in Q4 2025, and down 73.48% YoY from $31748.0 in Q1 2025.
Coya Therapeutics (COYA) Non-Current Assets (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Non-Current Assets for 6 years, with the latest figure at $8420.0 in Q1 2026.
- Quarterly Non-Current Assets fell 73.48% year-over-year to $8420.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62623.0 (down 62.73% YoY) and the FY2025 annual result came in at $11227.0, down 70.91% from the prior year.
- Non-Current Assets slipped to $8420.0 in Q1 2026 per COYA's latest filing, from $11227.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.2 million in Q4 2022 and troughed at $8420.0 in Q1 2026.
- A 5-year average of $128943.2 and a median of $48849.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets jumped 482.43% in 2022, then slumped 94.55% in 2023.
- Over 5 years, Non-Current Assets stood at $1.2 million in 2022, then plunged by 94.55% to $65949.0 in 2023, then plunged by 41.49% to $38588.0 in 2024, then plunged by 70.91% to $11227.0 in 2025, then slipped by 25.0% to $8420.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $8420.0, $11227.0, and $18068.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | 250,341.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 250,341.00 |
| Mar 31, 2026 | 8,420.00 |
| Dec 31, 2025 | 11,227.00 |
| Sep 30, 2025 | 18,068.00 |
| Jun 30, 2025 | 24,908.00 |
| Mar 31, 2025 | 31,748.00 |
| Dec 31, 2024 | 38,588.00 |
| Sep 30, 2024 | 45,429.00 |
| Jun 30, 2024 | 52,269.00 |
| Mar 31, 2024 | 59,109.00 |
| Dec 31, 2023 | 65,949.00 |
| Sep 30, 2023 | 72,790.00 |
| Jun 30, 2023 | 79,630.00 |
| Mar 31, 2023 | 86,470.00 |
| Dec 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 207,852.00 |